Xylazine

bradycardia, AV block, hypotension, heart failure

Individuals with pre-existing bradycardia, AV conduction abnormalities, or hypotension face heightened risk of hemodynamic compromise. Xylazine's alpha-2 mediated negative chronotropic and vasodilatory effects can produce clinically dangerous heart rates and blood pressures in susceptible individuals.

fentanyl, heroin, morphine, oxycodone, other opioid agonists

Co-administration with opioids (fentanyl, heroin, morphine, oxycodone) dramatically increases overdose risk. Xylazine potentiates fentanyl-induced brain hypoxia and eliminates rebound oxygen recovery. Naloxone reverses only the opioid component — xylazine effects persist, causing prolonged unconsciousness. In postmortem analyses, 98% of xylazine-positive opioid overdose deaths involved fentanyl.

benzodiazepines, alcohol, barbiturates, GHB, other sedative-hypnotics

Combination with benzodiazepines, alcohol, barbiturates, GHB, or other sedative-hypnotics produces additive CNS depression, increasing risk of respiratory arrest, aspiration, and death. Polydrug toxicity patterns in overdose death series confirm this interaction.

type 1 diabetes, type 2 diabetes, pre-diabetes

Xylazine inhibits insulin secretion via alpha-2 receptors on pancreatic beta cells. Individuals with diabetes mellitus or pre-diabetes may experience clinically significant hyperglycemia. Interaction with insulin, sulfonylureas, and other hypoglycemic agents is theoretically important.

pregnancy

Placental transfer of xylazine has been confirmed in a human case report via umbilical cord assay (Kasemodel 2026). Animal models demonstrate dose-dependent uterine vasoconstriction, reduced uteroplacental blood flow, fetal growth restriction, and pregnancy loss. Neonatal sedation and contribution to neonatal abstinence syndrome are possible. No controlled human pregnancy safety data exist.